Stock Movers on FDA Decision (BCRX, AZN, INO, GTXI)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) fell 1.13% to $5.23 on heavy volume after today announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company’s exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases.

AstraZeneca plc (ADR) (NYSE:AZN) fell 1.09% to $51.91 on heavy volume after it announced that they have received an extension from the U.S. FDA for a New Drug Application submission for ticagrelor (BRILINTA).

Accordingly, the FDA extended the Prescription Drug User Fee Act (PDUFA) date from September 16, 2010 to December 16, 2010. AstraZeneca said they will continue to work closely with the FDA to support the review of the ticagrelor NDA.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines for six areas of healthcare.

Inovio Pharmaceuticals, Inc. (AMEX:INO) plunged 2.73% to $1.13. it announces that they have received additional follow-on funding from the PATH Malaria Vaccine Initiative (MVI). The funding will aid in Inovio's development of malaria DNA vaccine candidate in non-human primates.

Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases.

You can Subscribe to these Free Stock Alerts by visiting:  http://www.PennyStockPickReport.com

GTx, Inc. (NASDAQ:GTXI) rose 4.13% to $3.28 after it announced today that a a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial of GTx-758 suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.

GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that targets hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions.

About http://www.PennyStockPickReport.com

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.